The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adlai Nortye Ltd. Sponsored ADR (ANL) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adlai Nortye Ltd. Sponsored ADR is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adlai Nortye Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has moved 39.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ANL has returned 727.8% so far this year. Meanwhile, the Medical sector has returned an average of -0.1% on a year-to-date basis. This shows that Adlai Nortye Ltd. Sponsored ADR is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Thermo Fisher Scientific (TMO). The stock has returned 14.4% year-to-date.
For Thermo Fisher Scientific, the consensus EPS estimate for the current year has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adlai Nortye Ltd. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual companies and currently sits at #152 in the Zacks Industry Rank. Stocks in this group have lost about 0.3% so far this year, so ANL is performing better this group in terms of year-to-date returns.
In contrast, Thermo Fisher Scientific falls under the Medical - Instruments industry. Currently, this industry has 78 stocks and is ranked #94. Since the beginning of the year, the industry has moved -5.5%.
Investors interested in the Medical sector may want to keep a close eye on Adlai Nortye Ltd. Sponsored ADR and Thermo Fisher Scientific as they attempt to continue their solid performance.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adlai Nortye Ltd. Sponsored ADR (ANL): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).